Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
09 avr. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
Global Hepatology Market Report 2023-2028: Highly Sensitive and Rapid Diagnostic Tests Propel Growth in the Hepatology Market
04 août 2023 08h13 HE
|
Research and Markets
Dublin, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Hepatology Market (2023-2028) by Product Type, Reagent, Application, End User, and Geography, Competitive Analysis, Impact of Economic Slowdown...
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
18 juil. 2023 09h29 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Global Human Liver Models Market to 2028: Featuring Ascendance Biotechnology, CN Bio Innovations, Cyfuse Biomedical, Emulate and Organovo Holdings Among Others
21 févr. 2023 13h03 HE
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Human Liver Models - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Liver...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
06 déc. 2022 08h10 HE
|
Invea Therapeutics
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...
Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization
07 déc. 2021 10h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M...
Velacur™ Data Presented at 2021 AASLD The Liver Meeting®
12 nov. 2021 08h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...
Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis
20 oct. 2020 10h00 HE
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver...
Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting
30 oct. 2019 08h05 HE
|
Cocrystal Pharma, Inc.
New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV)Eight of 12 patients achieved primary endpoint of sustained virologic response...
Capital Digestive Care Taps Ramsey Daher, MD for Its Metro Offices
14 févr. 2019 06h02 HE
|
Capital Digestive Care
Silver Spring, MD, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Capital Digestive Care welcomes Ramsey Daher, MD to its growing practice. Dr. Daher is now seeing patients at the company’s K Street, NW office...